Mednax Clinical Leadership Urges Full Vaccination and All Measures to Protect Expecting Mothers and Children During COVID-19 Pandemic
October 13 2021 - 6:45AM
Business Wire
Nation’s Leading Provider of Specialty
Maternity and Pediatric Care Advocates for Vulnerable Populations
and Those Unable to Become Vaccinated
Mednax®, Inc. (NYSE: MD), its clinical leadership, and that of
its affiliated Pediatrix® and Obstetrix® Medical Groups today
provided full support of the Centers for Disease Control and
Prevention (CDC) and other medical associations’ recommendations
that all eligible Americans become vaccinated against COVID-19.
This support is consistent with Mednax’s long-standing commitment
to the well-being of its affiliated medical practices’ patients
nationwide, who consist of women undergoing high-risk pregnancies,
critically ill and premature newborns and children in need of
specialized and, in many cases, critical care.
This recommendation is also consistent with that of leading
clinical associations, including The American College of
Obstetricians and Gynecologists, the Society for Maternal-Fetal
Medicine, and the American Academy of Pediatrics.
Similar to those for many other historical diseases, COVID-19
vaccinations have been proven as safe and effective. More than 400
million COVID-19 doses have been administered in the U.S. and 6.5
billion doses worldwide, and the overall benefits of the vaccine
cannot be disputed. Currently, as many as 90% or more of deaths
caused by COVID-19 are occurring in unvaccinated individuals, and
infections could be further mitigated by increasing the number of
fully vaccinated people.
Clinical leaders across the Mednax organization provided the
following statement:
“As clinicians, parents and caring citizens, we are acutely
aware of the devastating effect the COVID-19 virus can have on
those who have not been vaccinated, and in particular on those who
cannot be vaccinated, including newborns and young children. As
medical leaders, it is our responsibility to do all we can to
protect expecting mothers and children by following every
mitigation measure available. This includes proven measures to
prevent the virus’ spread including social distancing, masking,
hand washing and most importantly, becoming fully vaccinated if
eligible. Expecting mothers and children depend on us every day –
and they deserve nothing less than to live in an environment where
we are all collectively doing what we can to stop the spread of
this deadly virus. Maximizing the number of vaccinated individuals
not only helps to do just that, but also helps to safeguard the
health of those not eligible for the vaccine.”
Signed: Dr. Mack Hinson, Neonatology, President, Mednax Dr. Curt
Pickert, Pediatric Critical Care Medicine, President, Clinical
Services Division Dr. Renee Higgerson, Pediatric Critical Care
Medicine Dr. Jeff Kane, Pediatric Neurology Dr. Luissa Kiprono,
Maternal-Fetal Medicine Dr. John Loyd, Neonatology Dr. Ashish
Sureka, Pediatric Cardiology
ABOUT MEDNAX
Mednax, Inc. is a national medical group comprised of the
nation’s leading providers of physician services. Physicians and
advanced practitioners practicing as part of Mednax’s Pediatrix and
Obstetrix Medical Groups are reshaping the delivery of care within
their specialties and subspecialties, using evidence-based tools,
continuous quality initiatives, clinical research and telehealth
programs to enhance patient outcomes and provide high-quality,
cost-effective care. The Company was founded in 1979, and today,
through its affiliated professional entities, Mednax provides
services through a network of more than 2,300 physicians in 39
states and Puerto Rico. Additional information is available at
www.mednax.com.
Certain statements and information in this press release may be
deemed to contain forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, Section 27A
of the Securities Act of 1933, as amended (the “Securities Act”),
and Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements may include, but are not limited to,
statements relating to the Company’s objectives, plans and
strategies, and all statements, other than statements of historical
facts, that address activities, events or developments that we
intend, expect, project, believe or anticipate will or may occur in
the future. These statements are often characterized by terminology
such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,”
“plan,” “will,” “expect,” “estimate,” “project,” “positioned,”
“strategy” and similar expressions, and are based on assumptions
and assessments made by the Company’s management in light of their
experience and their perception of historical trends, current
conditions, expected future developments and other factors they
believe to be appropriate. Any forward-looking statements in this
press release are made as of the date hereof, and the Company
undertakes no duty to update or revise any such statements, whether
as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties. Important factors that
could cause actual results, developments, and business decisions to
differ materially from forward-looking statements are described in
the Company’s most recent Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q, including the sections entitled
“Risk Factors”, as well the Company’s current reports on Form 8-K,
filed with the Securities and Exchange Commission, and include the
impact of the COVID-19 pandemic on the Company and its financial
condition and results of operations; the effects of economic
conditions on the Company’s business; the effects of the Affordable
Care Act and potential changes thereto or a repeal thereof; the
Company’s relationships with government-sponsored or funded
healthcare programs, including Medicare and Medicaid, and with
managed care organizations and commercial health insurance payors;
the Company’s ability to comply with the terms of its debt
financing arrangements; the impact of the divestiture of the
Company’s anesthesiology and radiology medical groups; the impact
of management transitions; the timing and contribution of future
acquisitions; the effects of share repurchases; and the effects of
the Company’s transformation initiatives, including its
reorientation on, and growth strategy for, its pediatrics and
obstetrics business.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211013005377/en/
Charles Lynch Senior Vice President, Finance and Strategy
954-384-0175 ext. 5692 charles_lynch@mednax.com
Pediatrix Medical (NYSE:MD)
Historical Stock Chart
From May 2024 to Jun 2024
Pediatrix Medical (NYSE:MD)
Historical Stock Chart
From Jun 2023 to Jun 2024